Immediate Impact
2 from Science/Nature 58 standout
Citing Papers
Hepatocellular carcinoma: signaling pathways, targeted therapy, and immunotherapy
2024 Standout
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
2023 Standout
Works of John Joseph Wright being referenced
A phase I study of cabozantinib plus nivolumab (CaboNivo) and ipilimumab (CaboNivoIpi) in patients (pts) with refractory metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors.
2017
Characterization of CCX282-B, an Orally Bioavailable Antagonist of the CCR9 Chemokine Receptor, for Treatment of Inflammatory Bowel Disease
2010
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| John Joseph Wright | 81 | 139 | 72 | 89 | 31 | 307 | |
| Akira Gochi | 75 | 165 | 117 | 51 | 29 | 356 | |
| Hyeong Chan Shin | 103 | 142 | 86 | 86 | 22 | 349 | |
| T Toge | 113 | 141 | 113 | 43 | 29 | 321 | |
| Simona Pigozzi | 50 | 117 | 100 | 60 | 24 | 310 | |
| Norimichi Kan | 143 | 136 | 35 | 84 | 35 | 342 | |
| Baojun Huang | 81 | 65 | 122 | 151 | 29 | 353 | |
| Rahul Hejmadi | 58 | 135 | 75 | 86 | 34 | 371 | |
| J.-O. Bay | 82 | 135 | 76 | 84 | 24 | 363 | |
| Yuichi Terado | 123 | 104 | 97 | 50 | 27 | 352 | |
| Tatsuki Nanami | 99 | 182 | 100 | 102 | 36 | 339 |
All Works
Loading papers...